Meprobamate

{{DrugProjectFormSinglePage |authorTag=Kiran Singh, M.D. [1] |genericName=meprobamate |aOrAn=a |drugClass=antianxiety |indicationType=treatment |indication=anxiety disorders |adverseReactions=Central Nervous System

Drowsiness, ataxia, dizziness, slurred speech, headache, vertigo, weakness, paresthesias, impairment of visual accommodation, euphoria, overstimulation, paradoxical excitement, fast EEG activity.

Gastrointestinal

[[Nausea, vomiting, diarrhea.

Cardiovascular

Palpitation, tachycardia, various forms of arrhythmia, transient ECG changes, syncope; also hypotensive crisis (including one fatal case).

Allergic or Idiosyncratic

Allergic or idiosyncratic reactions are usually seen within the period of the first to fourth dose in patients having had no previous contact with the drug. Milder

reactions are characterized by an itchy, urticarial, or erythematous maculopapular rash which may be generalized or confined to the groin. Other reactions have

included leukopenia, acute nonthrombocytopenic purpura, petechiae, ecchymoses, eosinophilia, peripheral edema, adenopathy, fever, fixed drug eruption with cross

reaction to carisoprodol, and cross sensitivity between meprobamate/mebutamate and meprobamate/carbromal.

More severe hypersensitivity reactions, rarely reported, include hyperpyrexia, chills, angioneurotic edema, bronchospasm, oliguria and anuria. Also, anaphylaxis,

erythema multiforme, exfoliative dermatitis, stomatitis, proctitis, Stevens-Johnson syndrome and bullous dermatitis, including one fatal case of the latter following

administration of meprobamate in combination with prednisolone.

In case of allergic or idiosyncratic reactions to meprobamate, discontinue the drug and initiate appropriate symptomatic therapy, which may include epinephrine,

antihistamines, and in severe cases, corticosteroids. In evaluating possible allergic reactions, also consider allergy to excipients.

Hematologic

(See also Allergic or Idiosyncratic.) Agranulocytosis and aplastic anemia have been reported. These cases rarely were fatal. Rare cases of thrombocytopenic

purpura have been reported.

Other Exacerbation of porphyric symptoms. |blackBoxWarningTitle=ConditionName: |blackBoxWarningBody=ConditionName:

• Content

|fdaLIADAdult======Condition1=====

• Dosing Information

• Dosage

Condition2

• Dosing Information

• Dosage

Condition3

• Dosing Information

• Dosage

Condition4

• Dosing Information

• Dosage

|offLabelAdultGuideSupport======Condition1=====

• Developed by:

• Class of Recommendation:

• Strength of Evidence:

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Meprobamate in adult patients.

|offLabelAdultNoGuideSupport======Condition1=====

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Meprobamate in adult patients.

|fdaLIADPed======Condition1=====

• Dosing Information

• Dosage

Condition2

There is limited information regarding FDA-Labeled Use of Meprobamate in pediatric patients.

|offLabelPedGuideSupport======Condition1=====

• Developed by:

• Class of Recommendation:

• Strength of Evidence:

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Meprobamate in pediatric patients.

|offLabelPedNoGuideSupport======Condition1=====

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Meprobamate in pediatric patients.

|contraindications=* Condition1

|warnings=* Description

Precautions

• Description

|clinicalTrials=There is limited information regarding Clinical Trial Experience of Meprobamate in the drug label.

Miscellaneous

|postmarketing=There is limited information regarding Postmarketing Experience of Meprobamate in the drug label.

Miscellaneous

|drugInteractions=* Drug

• Description

|useInPregnancyFDA=* Pregnancy Category |useInPregnancyAUS=* Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Meprobamate in women who are pregnant. |useInLaborDelivery=There is no FDA guidance on use of Meprobamate during labor and delivery. |useInNursing=There is no FDA guidance on the use of Meprobamate with respect to nursing mothers. |useInPed=There is no FDA guidance on the use of Meprobamate with respect to pediatric patients. |useInGeri=There is no FDA guidance on the use of Meprobamate with respect to geriatric patients. |useInGender=There is no FDA guidance on the use of Meprobamate with respect to specific gender populations. |useInRace=There is no FDA guidance on the use of Meprobamate with respect to specific racial populations. |useInRenalImpair=There is no FDA guidance on the use of Meprobamate in patients with renal impairment. |useInHepaticImpair=There is no FDA guidance on the use of Meprobamate in patients with hepatic impairment. |useInReproPotential=There is no FDA guidance on the use of Meprobamate in women of reproductive potentials and males. |useInImmunocomp=There is no FDA guidance one the use of Meprobamate in patients who are immunocompromised.

|administration=* Oral

• Intravenous

|monitoring=There is limited information regarding Monitoring of Meprobamate in the drug label.

• Description

|IVCompat=There is limited information regarding IV Compatibility of Meprobamate in the drug label.

|overdose====Acute Overdose===

Signs and Symptoms

• Description

Management

• Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Meprobamate in the drug label.

|drugBox= |mechAction=*

|structure=*

File:Meprobamate01.png

This image is provided by the National Library of Medicine.

|PD=There is limited information regarding Pharmacodynamics of Meprobamate in the drug label.

|PK=There is limited information regarding Pharmacokinetics of Meprobamate in the drug label.

|nonClinToxic=There is limited information regarding Nonclinical Toxicology of Meprobamate in the drug label.

|clinicalStudies=There is limited information regarding Clinical Studies of Meprobamate in the drug label.

|howSupplied=* |packLabel= |fdaPatientInfo=There is limited information regarding Patient Counseling Information of Meprobamate in the drug label.

|alcohol=* Alcohol-Meprobamate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

|brandNames=* ®

|lookAlike=* A® — B®

|drugShortage= }} {{#subobject:

 |Page Name=Meprobamate
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Meprobamate
 |Label Name=Meprobamate11.png

}}

{{#subobject:

 |Label Page=Meprobamate
 |Label Name=Meprobamate11.png

}}